BCWORLD PHARM. Co., Ltd.
Financials
Valuation Metrics
BCWORLD PHARM. Co., Ltd.'s Market Cap is ₩320B. At end of 2025 it was ₩588B. Ranked #2047 of 2,421 in KR market (top 85%), #1306 of 1,640 on KOSDAQ (top 80%), #214 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 93%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 32.00B KRW | KR#2,047/2,421 Sec#214/231 |
| Revenue | 80.33B KRW | KR#1,548/2,421 Sec#98/231 |
| Net Income | -1.26B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 176.80B KRW | KR#1,392/2,421 Sec#104/231 |
| Net Assets | 72.50B KRW | KR#1,653/2,421 Sec#138/231 |
| Employees | 281 | KR#840/2,421 Sec#71/231 |
| Value | ||
| P/B | 0.44x | KR#663/2,421 Sec#24/231 |
| P/S | 0.40x | KR#766/2,421 Sec#27/231 |
| EV/EBITDA | 40.30x | KR#1,290/2,421 Sec#82/231 |
| Profitability | ||
| ROE | -1.74% | KR#1,671/2,421 Sec#115/231 |
| ROA | -0.71% | KR#1,639/2,421 Sec#112/231 |
| Op. Margin | 3.51% | KR#1,163/2,421 Sec#85/231 |
| Revenue Growth | 6.65% | KR#1,095/2,421 Sec#107/231 |
| Earnings Growth | -181.78% | KR#1,228/2,421 Sec#82/231 |
| Financial Health | ||
| Debt Ratio | 143.86% | KR#1,872/2,421 Sec#206/231 |
| Total Debt | 87.53B KRW | KR#777/2,421 Sec#48/231 |
| Cash | 5.88B KRW | KR#1,949/2,421 Sec#175/231 |
| Current Ratio | 0.53x | KR#2,126/2,421 Sec#204/231 |
| Net Debt/EBITDA | 28.95x | KR#1,427/2,421 Sec#101/231 |
| Dividend | ||
| Div. Yield | 3.05% | KR#622/2,421 Sec#30/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -24.87% | KR#1,401/2,421 Sec#102/231 |
| 1M Return | -1.15% | KR#1,367/2,421 Sec#103/231 |
| From 52W High | -50.25% | KR#1,405/2,421 Sec#107/231 |
| 1Y MDD | -49.57% | KR#967/2,421 Sec#78/231 |
| Trading | ||
| Volume | 1,907 shares | KR#2,277/2,421 Sec#214/231 |
| Trading Value | 5.7M KRW | KR#2,328/2,421 Sec#221/231 |
| Foreign Own. | 1.21% | KR#1,943/2,421 Sec#190/231 |
| Per Share | ||
| EPS | -119 KRW | KR—/2,421 Sec—/231 |
| BPS | 6,798 KRW | KR#1,267/2,421 Sec#88/231 |
Company Info
BC World Pharm, established in 1980 and renamed in 2007, was certified as an innovative pharmaceutical company in 2012, a status it holds until 2024. The company specializes in pharmaceutical manufacturing and sales, leveraging EU GMP/cGMP-level facilities to expand its domestic and international Contract Manufacturing Organization (CMO)/Contract Development and Manufacturing Organization (CDMO) businesses and exports to advanced and emerging markets. As an R&D-focused pharmaceutical company with original Drug Delivery System (DDS) technology, it invests about 12% of its sales into R&D, growing into a global healthcare enterprise. BC World Pharm is headquartered in Gyeonggi-do, Yeoju-si.